RLRichard Larivière

Richard Larivière

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Richard Larivière has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Marcel Lebel

    Division of Nephrology, L’Hôtel-Dieu de Québec Hospital and l’Université Laval, Quebec, Canada

    4 shared publications
  • Marcel Lebel

    CHUQ Research Center and Division of Nephrology & Hypertension, L'Hôtel-Dieu de Québec Hospital and Department of Medicine, Laval University, Quebec, Canada

    3 shared publications
  • B. Falardeau

    1 shared publication
  • Caron L.A

    Research Centre and Division of Nephrology, CHUQ, L’Hôtel-Dieu de Québec Hospital, and Departments of bPharmacology and cMedicine, Laval University, Quebec, Canada

    1 shared publication
  • Claudia Moreau

    Research Centre and Division of Nephrology, CHUQ, L’Hôtel-Dieu de Québec Hospital and Department of Medicine, Laval University, Quebec, Canada

    1 shared publication
  • D’amours M.A

    Research Centre and Division of Nephrology, CHUQ, L’Hôtel-Dieu de Québec Hospital, and Departments of bPharmacology and cMedicine, Laval University, Quebec, Canada

    1 shared publication

Latest Publications

  • Increased ET-1 and Reduced ETBReceptor Expression in Uremic Hypertensive Rats

    by Martin D'AMours, Nadia Chbinou, Jonathan Beaudoin, Marcel Lebel, Richard Larivière

    The endothelin-1 (ET-1) system has been implicated in cardiovascular disease associated with chronic renal failure. We investigated the expression and localization of ET-1 and the ETB and ETA receptors in vascular and renal tissues of uremic hypertensive rats. Uremia was induced by renal artery branches ligation. At week 6, blood and renal parameters, and plasma and urine ET-1 levels were evaluated. The ET-1, and the ETB and ETA receptors expression and localization were determined by Northern and Western blotting, and by immunofluorescence, respectively. Blood pressure, serum creatinine, proteinuria, and urinary ET-1 were increased in uremic rats. The ET-1 expression was increased in the aorta, mesenteric arteries, and the renal cortex of uremic rats, whereas the ETB receptor expression was reduced. Immunofluorescence analysis using the thoracic aorta revealed that the endothelial ET-1 levels were increased 4-fold in uremic rats. In contrast, the ETB receptor expression, which was localized exclusively in the endothelium, was markedly reduced. The ETA receptor expression, however, was increased 1.6-fold and was detected in the media only. Similar changes in ET-1 and ETB receptor expression were observed in renal cortex vessels and glomeruli of uremic rats. This study reveals that ET-1 levels are augmented in the vascular endothelium of uremic rats, whereas the ETB receptor expression is reduced which may play a major role in hypertension and renal failure progression.


  • Endothelin-1 in chronic renal failure and hypertension

    by Richard Larivière, Marcel Lebel

    Investigation into the role of endothelin-1 (ET-1) in renal function has revealed two major direct actions leading to the control of extracellular volume and blood pressure. These are the regulation of renal hemodynamics and glomerular filtration rate and the modulation of sodium and water excretion. In the rat remnant kidney model of chronic renal failure, ET-1 production is increased in blood vessels and renal tissues. These changes are related to an increase in preproET-1 expression and correlate with the rise in blood pressure, the development of cardiovascular hypertrophy, and the degree of renal insufficiency and injury. Selective ETAreceptor blockade prevents the progression of hypertension and the vascular and renal damage, supporting a role for ET-1 in chronic renal failure progression. The increase in ET-1 production can be associated with other local mediators, including angiotensin II, transforming growth factor-β1 and nitric oxide, the local production of which is also altered in chronic renal failure. In human patients with essential hypertension, atherosclerosis, and nephrosclerosis, plasma ET-1 levels are increased compared with patients with uncomplicated essential hypertension. Similarly, plasma ET-1 concentrations are markedly increased in patients with end-stage renal disease undergoing dialysis, and this correlates with blood pressure, suggesting that ET-1 may contribute to hypertension in these patients. The treatment of anemia in patients with renal failure with human recombinant erythropoietin increases blood pressure by accentuating the underlying endothelial dysfunction and the elevated vascular ET-1 production. Overall, these results support a role for ET-1 in hypertension and the end-organ damage associated with chronic renal failure. ETAreceptor blockade may then represent a potential target for the management of hypertension and cardiovascular and renal protection.Key words: endothelin-1, angiotensin II, nitric oxide, erythropoietin, chronic renal failure, hypertension, endothelium.


    • 1 March 1999
      • Vol. 77  (3) , 188-94

    Nonpeptide endothelin receptor antagonists attenuate the pressor effect of diaspirin-crosslinked hemoglobin in rat.

    by F Rioux, N Harvey, S Moisan, R Larivière, M Lebel, J H Grose, K Burhop

    Endothelin 1 (ET-1) is a potent vasoactive and mitogenic peptide that is thought to participate in the hemodynamic effects elicited by drugs that block the biosynthesis and release of endothelium-derived nitric oxide (NO), such as NO synthase inhibitors. Using the nonpeptide endothelin receptor antagonists bosentan and LU-135252, we tested the hypothesis that endothelins contribute to the pressor activity of diaspirin-crosslinked hemoglobin (DCLHb), a hemoglobin-based oxygen carrier, whose pressor activity in mammals is attributed primarily to a scavenging action towards NO. The NO synthase inhibitor nitro-L-arginine methyl ester (L-NAME), ET-1, and noradrenaline (NA) were used as reference drugs. Bosentan markedly reduced the pressor effects elicited by DCLHb, L-NAME, and ET-1, but not those evoked by NA. LU-135252 attenuated the pressor effect elicited by DCLHb and ET-1, but not that produced by L-NAME or NA. The decreases in heart rate associated with the pressor effect of DCLHb and L-NAME were reduced by LU-135252, whereas only those elicited by DCLHb were attenuated by bosentan. In contrast with bosentan, LU-135252 caused a decrease in the baseline blood pressure and heart rate. These results suggest that endothelins may participate in the pressor activity of DCLHb. They suggest also that nonpeptide endothelin receptor antagonists such as bosentan or LU-135252 may be useful to counteract endothelin-mediated undesirable hemodynamic effects of drugs that inhibit the activity of the NO system.

  • 2.P.244 Relatinship between plasma endothelin-1, HDL-C and systolic blood pressure in renal transplant recipients

    by T. Radeau, M. Lebel, I. Houde, I. Kigma, R. Larivière, J.G. Lachance, R. Noel, P. Douville, J. Bergeron

  • Increased Immunoreactive Endothelin-1 Levels in Blood Vessels and Glomeruli of Rats with Reduced Renal Mass

    by Larivière R.B, D’amours M.A, Lebel M.C, Kingma I.C, Grose J.H.C, Caron L.A

    Elevated plasma and urinary endothelin-1 (ET-1) levels have been reported in patients with renal failure as well as in remnant kidney models of chronic renal failure. We investigated whether these changes are related to increased ET-1 production in cardiovascular and renal tissues of rats with reduced renal mass. In uremic rats, systolic blood pressure rose in parallel with the progression of renal insufficiency. At week 6, changes in systolic blood pressure were positively correlated with serum creatinine levels (r = 0.728, p < 0.01). Plasma immunoreactive ET-1 (ir-ET-1) concentration was similar in uremic rats and sham-operated controls. In contrast, urinary ir-ET-1 excretion was significantly greater in uremic rats and was correlated with the elevation of serum creatinine and proteinuria (r = 0.795, and 0.922, p < 0.01, respectively). Compared to the controls, ir-ET-1 concentration in the thoracic aorta, preglomerular arteries and glomeruli were 1.4-, 3.5- and 6.7-fold higher, respectively, in uremic rats (p < 0.01) than in the controls. However, ir-ET-1 concentration in the mesenteric arterial bed and the left ventricle remained similar in the 2 groups, whereas it was significantly lower in the renal papilla of uremic rats (p < 0.01). Thus, ET-1 production is unchanged or slightly increased in extrarenal cardiovascular tissues of rats with reduced renal mass. In contrast, ET-1 production is significantly augmented in preglomerular arteries and glomeruli, but reduced in the papilla, suggesting that increased urinary ir-ET-1 excretion in uremic rats reflects ET-1 overproduction in the former renal tissues. Elevated ET-1 production in blood vessels and glomeruli may thus play a key role in the aggravation of hypertension and the progression of renal insufficiency in this rat remnant kidney model of chronic renal failure.